Area growth outpaces market value
CropLife Brasil‘s data platform CropData reported 9.6% year-on-year sales growth between January and June. The expansion in treated area was almost twice the growth in sales. That pattern indicates broader adoption across farms, rather than only higher spending among existing users.
Bioinsecticides led the market. Sales reached R$858.2m, or 47% of the total, while applications covered 16.4m hectares. The category benefited from Brazil’s second-crop maize cycle. According to consultancy Blink, adoption reached 35% during the 2025/26 season, with products targeting maize leafhoppers and armyworms.
Meanwhile, bionematicides recorded stronger area growth. Sales rose 11.8% to R$542.8m, while treated area climbed 36.7% to 15.1m hectares. Blink data put adoption at about 35% in soybeans and 56% in cotton, pointing to increasing use against plant-parasitic nematodes.
Biofungicides lead sales growth
Biofungicides generated R$311.5m during the period. Their sales grew 19.8% — the fastest increase among the main product groups. However, inoculants moved differently. Sales fell 21.5% to R$107m, while treated area increased 38.6% to 9.4m hectares.
Inoculants have strong links with soybean production. Adoption exceeds 90%, according to CropLife Brasil’s summary, and purchasing typically accelerates with seed sales. That seasonal dynamic is a key factor shaping second-half revenue expectations.
Brazil’s broader farm output context adds further weight. Farm output hit a record R$927bn in 2025, and biological inputs are increasingly embedded in that growth story as growers seek to protect yields while managing resistance pressures.
What does the market mean for investors?
The sales cycle should strengthen from June through November and December. Farmers typically buy biological fungicides, nematicides and inoculants before soybean planting. That seasonal pattern matters for companies planning inventory, working capital and production capacity.
Brazil added 61 biological products with active registrations between January and 24 September, according to Move Analytics, which compiled the figure from official Agriculture Ministry data and the Agrofit database. Microbiological agents accounted for 44 registrations. Macrobiological agents added nine, while biochemical products accounted for eight.
The pipeline is growing, but approvals are taking longer. Average registration times reached about 20 months for biological products in 2026, compared with 15 months in 2025. For biological and organic products, the average increased to 16 months from 14 months. Slower approvals could limit product launches, despite rising farm-level demand.
The central market signal
Brazil is expanding biological use faster than biological spending — and that gap is the defining characteristic of this market’s current phase. As reported by AgFeed, the data supports a growth case for suppliers with differentiated products, strong distribution and dependable registration pipelines.
However, investors should track approvals, soybean planting, seasonal purchasing and price discipline. The next market test will be second-half sales as soybean preparation gathers pace and companies convert wider treated acreage into recurring revenue.
Quick answers
Brazil’s bioinputs market generated R$1.82bn (approximately US$330m) in the first half of 2026, with sales up 9.6% year-on-year and treated farmland expanding 18.3% to 46.2m hectares.
Biofungicides recorded the fastest sales growth at 19.8%, generating R$311.5m, while bioinsecticides led overall market value at R$858.2m or 47% of total sector sales.
Average registration times for biological products reached about 20 months in 2026, up from 15 months in 2025, according to Move Analytics data compiled from the official Agrofit database — a delay that could limit new product launches despite strong farm-level demand.
